Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Leptin administration Clear all

Conditions: HIV Infections, Lipodystrophy
Interventions: Leptin, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 14 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Health Adult Subjects
Interventions: Placebo （Microcrystalline Cellulose）, Dihydroberberine（DHB）; Dietary Supplement
Lead sponsor: Nanjing Nutrabuilding Bio-tech Co., Ltd.; Other
Eligibility: 35 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Genetic Obesity
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Scottsdale, Arizona • Suwanee, Georgia • Worcester, Massachusetts + 16 more

Conditions: Lipodystrophy, Diabetes, Hyperlipidemia
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months to 98 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Familial Partial Lipodystrophy, Metabolic Abnormalities
Interventions: REGN4461, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Boca Raton, Florida • Bethesda, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Sleep Apnea, Sleep Disordered Breathing
Interventions: liraglutide; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions: r-metHuLeptin, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertriglyceridemia, Obesity
Interventions: Setmelanotide; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 15 Years to 15 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission
Interventions: nutritional intervention, exercise intervention, follow-up care, counseling intervention, quality-of-life assessment, laboratory biomarker analysis, questionnaire administration; Dietary Supplement · Behavioral · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lipodystrophy
Interventions: hu Leptin (A-100); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Leptin administration, Fasting; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 5 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Months and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overweight, Obesity, Small for Gestational Age, Prematurity
Interventions: Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool; Other
Lead sponsor: Duke University; Other
Eligibility: 1 Hour to 18 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pituitary Dwarfism, Idiopathic Short Stature
Interventions: Not listed
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Jacksonville, Florida

Conditions: Generalized Lipodystrophy
Interventions: Placebo, Low-Dose REGN4461, High-dose REGN4461; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas

Conditions: Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fatty Liver Disease, Nonalcoholic
Interventions: metreleptin; Drug
Lead sponsor: Elif Oral; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 1 Diabetes
Interventions: Leptin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Childhood Obesity
Interventions: Family Based Behavioral Treatment; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 9 Years to 11 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Lymphedema
Interventions: Bilateral arm measurements, Body mass index (BMI), Quality of Life Questionnaire, Blood draw; Other · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Familial Partial Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Birmingham, Alabama • Boca Raton, Florida • Boston, Massachusetts + 4 more

Conditions: Obesity
Interventions: Leptin, Very Low Calorie Diet; Drug · Behavioral
Lead sponsor: Rockefeller University; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Therapeutic Approaches to HAART-Induced Lipodystrophy

Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

Setmelanotide in a Single Patient With Partial Lipodystrophy

ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients

Leptin to Treat Lipodystrophy

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

Leptin to Treat Lipodystrophy

Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World

Pharmacodynamics of CNP During Growth Hormone Treatment

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Effect of Thiazolidinediones on Human Bone

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

Effects of Metreleptin in Type 1 Diabetes Mellitus

Brain Activation and Satiety in Children: Functional Magnetic Resonance Imaging

Lymphedema Surveillance Study

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Effects of Leptin Treatment on Weight Loss